The GLP-1 Lawsuits Explained: What to Know and What to Watch

If you have spent any time online lately, you have probably seen the videos: dramatic music, alarming captions, and claims about GLP-1 medications and a growing wave of lawsuits. If you take one of these medications, that is genuinely unsettling to scroll past. So let's do the calm, useful thing: walk through what is actually being litigated, what the science currently shows, and what is worth keeping an eye on as all of this develops.

This is not legal or medical advice, and it is not a reason to panic. It is a clear-eyed look at where things stand right now, so you can make informed decisions with your own healthcare provider. We will be following this closely and updating our understanding as it unfolds.

What Are the GLP-1 Lawsuits Actually About?

The GLP-1 lawsuits are consolidated product-liability cases alleging that manufacturers failed to adequately warn users about the risk of severe gastrointestinal issues like gastroparesis and certain vision changes. Manufacturers deny these allegations, and the litigation remains in its early pretrial stages.

Here is the factual picture, straight from the federal court docket. Thousands of complaints have been consolidated into two federal multidistrict litigations, or MDLs, before Judge Karen Marston in the Eastern District of Pennsylvania.^[1] One, MDL-3094, focuses on gastrointestinal injuries such as gastroparesis, intestinal blockages, and ileus. As of the Judicial Panel on Multidistrict Litigation's September 1, 2026 statistics report, MDL-3094 had 4,022 actions pending.^[1] A separate one, MDL-3163, created in late 2025, focuses on NAION, a rare form of vision loss, and had 216 actions pending as of that same report.^[1] The core legal argument in both is "failure to warn," meaning plaintiffs claim the drug labels did not sufficiently disclose the potential severity of these side effects. The cited sources describe both proceedings as early pretrial and discovery matters and reported no trials, verdicts, or settlements at that time. One significant pretrial ruling has already landed. In August 2025, the court excluded two of the plaintiffs' experts, holding that a plaintiff claiming drug-induced gastroparesis must have been diagnosed with a gastric emptying study rather than clinical impression alone.^[2] The court noted the ruling would affect relatively few of the cases in the MDL, but it shows how much is still being worked out well before any trial. The manufacturers, Novo Nordisk and Eli Lilly, deny the allegations and are actively defending their products.

We take a closer, calmer look at each of the two main injuries in their own guides: what gastroparesis, or "stomach paralysis," really means, and what to know about NAION and vision changes.

Is There Really a Two Billion Dollar Lawsuit?

Large figures are being discussed, but it helps to understand what they are. At this stage, there is no court verdict or settlement awarding two billion dollars; that widely repeated number traces back to a personal injury law firm's website, which cited unnamed analysts without showing how the figure was calculated. A fact-check found no public evidence supporting it.

We mention this not to minimize anything, real people are describing real and serious experiences, but simply so the numbers have context. When Snopes went looking for the origin of the two-billion-dollar figure in August 2025, the trail ended at a personal injury firm's website citing analysts it did not name, with no documentation showing how the number was reached. Snopes rated the underlying claim "Mostly True" on the existence of the litigation and "Undetermined" on the dollar amount.^[3] The figure resurfaced a year later in the videos now circulating. No court has awarded that amount. This is a genuine, ongoing legal process, and where it ultimately lands is still being determined. We are following it closely and will keep an eye on how it develops.

What Do We Actually Know So Far?

Some GLP-1 risks are well documented, including delayed gastric emptying, gastrointestinal symptoms, and a reported association with a rare form of vision loss. Other concerns circulating in the broader conversation are still emerging, and they are worth watching carefully as more evidence comes in.

It helps to sort the current conversation into what is already documented and what is still coming into focus.

What the science currently documents:

• Gastrointestinal side effects (nausea, vomiting, diarrhea) and delayed gastric emptying are real, common, and listed on the FDA labels.^[4]
• A retrospective Harvard study reported an association with an increased risk of NAION, a rare form of vision loss, in semaglutide users.^[5] European regulators reviewed the evidence and concluded that NAION is a very rare side effect of semaglutide, meaning it may affect up to 1 in 10,000 people taking it, and added it to the product labeling.^[6] The World Health Organization issued a parallel statement advising patients to contact a doctor without delay if vision changes occur, and that semaglutide should be stopped if NAION is confirmed.^[7]
• Lean-mass loss during rapid weight loss is well studied, but the proportion varies by study, medication, population, and measurement method. Study-specific body-composition findings should not be treated as one universal percentage.^[8]

What is still being raised and worth watching:

• Some of the figures and more striking descriptions circulating online are part of the current public conversation but are not yet established one way or the other. The August 2026 post that drove much of this wave claimed patients are "losing DECADES of muscle in a SINGLE YEAR," a description far more dramatic than what the published body-composition data actually shows. Time and evidence will tell, and we are watching closely.
• The active MDLs are currently centered on gastrointestinal injuries and NAION; other concerns being discussed publicly are not, at this point, the named legal basis of those cases.
• As with any fast-moving story, the full picture will take time to become clear. New data and filings could shift the understanding, which is exactly why staying informed matters.

Should You Be Worried About Muscle Loss on a GLP-1?

Muscle loss is a real and well-documented consideration during rapid weight loss, and it deserves genuine attention. The reassuring part is that it is also manageable for many people: protecting your lean mass generally involves a structured routine built around adequate protein intake and progressive resistance exercise.

This one is worth taking seriously, not because of any single video, but because the underlying science is solid: rapid weight loss can cost lean mass, and maintaining muscle supports strength and physical function. The genuinely good news is that it responds well to standard, sustainable habits, which puts a large part of this squarely back in your hands. We walk through exactly how in how to lose fat on GLP-1s without losing muscle, protein on GLP-1s, and resistance training on a GLP-1.

What Can You Actually Control?

You cannot control courtroom litigation, but you can control your daily nutrition, hydration, and medical oversight. Partnering with your prescribing provider to monitor any severe symptoms, staying well hydrated, and prioritizing nutrient density are the most useful tools within your reach.

Split it into two lanes. The medical lane belongs to your provider: contact them promptly if you experience severe or persistent GI symptoms, such as vomiting for more than 24 hours or an inability to keep food down, or any sudden vision changes. Do not try to self-manage those. The nutrition lane is where your daily choices live: supporting your digestion, keeping your fluids and electrolytes balanced, protecting your muscle, and staying ahead of the nutrient gaps that reduced food intake can quietly open.^[9] For a practical plate blueprint that makes every bite count, see what to eat on a GLP-1. Start with what GLP-1s do to your digestion, hydration on a GLP-1, and, if you are tapering off, coming off a GLP-1. Here is the genuinely empowering part: you cannot control how the litigation unfolds, but you can get a clear read on your own body. An HTMA test may provide complementary, non-diagnostic mineral-pattern context, but it does not diagnose deficiencies, heavy-metal toxicity, or injuries and cannot replace clinician-ordered testing. And if you believe you have experienced a serious injury, that is a conversation for a licensed attorney and your doctor, not a blog.

Frequently Asked Questions

Is Ozempic or Wegovy being recalled because of the lawsuits?

The cited sources do not identify a recall. GLP-1 products remain FDA-approved for their approved uses, but approval status and safety communications can change. Ongoing litigation is a separate legal process and does not by itself mean a product has been pulled from the market.

Do the lawsuits mean GLP-1s are proven unsafe?

Not on their own. The lawsuits are legal allegations centered on a claimed failure to adequately warn users, which the manufacturers are actively defending. Early-stage litigation reflects claims that still have to be worked through, rather than a settled conclusion in either direction.

Is muscle loss the main reason people are suing?

The active federal MDLs are currently centered on gastrointestinal injuries and NAION vision changes. Muscle loss is a real health consideration in its own right, but at this point it is not the named legal basis of those cases.

What should I do if I am experiencing severe stomach pain?

Contact your healthcare provider promptly to rule out serious conditions like pancreatitis or gallbladder issues. Severe, persistent GI symptoms are always worth a call to your provider rather than waiting them out.

Following It Closely

The GLP-1 lawsuits are real, ongoing, and worth understanding. They are also legal proceedings still in their early stages, so the full picture will take time to come into focus. Real risks exist and deserve real attention with your provider, and the questions being raised deserve to be taken seriously and watched carefully. Either way, the most productive thing you can do is focus on what you control: your muscle, your hydration, your nutrition, and honest communication with your doctor. If you need to know whether a symptom or suspected deficiency warrants clinical testing, your healthcare provider can guide that evaluation. For the full foundation, start with the hidden nutrient gaps behind GLP-1 weight loss. If you also want complementary, non-diagnostic mineral-pattern context, an HTMA test may be useful, but it does not replace medical testing. We will keep following this as it develops.

Rapid change on the outside. Steady support on the inside. Your minerals and nutrients, in your control.

References

1. In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094 (gastrointestinal injuries) and In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, MDL No. 3163 (NAION vision loss). Both before Judge Karen S. Marston, U.S. District Court for the Eastern District of Pennsylvania, 2024-2026. Official court sources: MDL-3094 and MDL-3163. Docket counts from JPML Pending MDL Dockets by Actions Pending, September 1, 2026. (Consolidated failure-to-warn allegations; 4,022 actions pending in MDL-3094 and 216 in MDL-3163 as of September 1, 2026; early pretrial stages; manufacturers deny the allegations and are defending.)
2. In re Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094, 2025 WL 2396801 (E.D. Pa. Aug. 15, 2025) (Marston, J.). Docket: MDL 3094 orders, E.D. Pa. (Court excluded two plaintiffs' experts under Rule 702, holding that drug-induced gastroparesis claims require diagnosis by gastric emptying study rather than differential diagnosis alone.)
3. Esposito J. Ozempic, other weight-loss drug makers face lawsuits. Here's what we know. Snopes; August 20, 2025. snopes.com/fact-check/ozempic-2-billion-lawsuit. (Rated "Mostly True" on the existence of the litigation, "Undetermined" on the dollar figure. Traced the two-billion-dollar number to a plaintiff law firm's website citing unnamed analysts with no supporting documentation.)
4. WEGOVY (semaglutide) injection, Prescribing Information. U.S. Food and Drug Administration; via DailyMed, U.S. National Library of Medicine. (Gastrointestinal side effects and delayed gastric emptying listed on the label.)
5. Hathaway JT, Shah MP, Hathaway DB, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol. 2024;142(8):732-739. doi:10.1001/jamaophthalmol.2024.2296 · PMID 38958939 · PMC11223051. (Retrospective matched cohort, Mass Eye and Ear / Harvard Medical School; reported association with elevated NAION risk in semaglutide users. NAION remains rare.)
6. European Medicines Agency, Pharmacovigilance Risk Assessment Committee. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. June 6, 2025. ema.europa.eu. ("NAION is a very rare side effect of semaglutide (meaning it may affect up to 1 in 10,000 people taking semaglutide).")
7. World Health Organization. The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION). June 27, 2025. who.int. (Patients should contact their doctor without delay if vision changes occur; semaglutide should be stopped if NAION is confirmed.)
8. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. doi:10.1111/dom.16275. (Lean-mass estimates vary across trials and body-composition analyses.)
9. Urbina J, et al. Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review. Clin Obes. 2026;16(1):e70070. doi:10.1111/cob.70070. (Reduced food-intake context and the value of monitoring nutrient status.)

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.